The COSMID (Comparison of Surgery and Medicine on the Impact of Diverticulitis) trial is a pragmatic, patient-level randomized superiority trial of elective colectomy vs. best medical management for patients with quality of life (QoL) limiting diverticular disease. A parallel observational cohort will include those who are disinclined to have their treatment choice randomized but are willing to contribute information about their outcomes.

This study is evaluating an investigational device (also known as the “study device”) called GATT-Patch as a possible management of minimal to moderate bleeding during liver surgery. An investigational device is one that has not been approved by the United States (US) Food and Drug Administration (FDA). 
   

The purpose of this study is to calculate the amount of oxygen in bowel tissue with the ViOptix Intra.Ox™ device. The creation of a healthy and safe colorectal anastomosis, where the colon is attached to the remainder of the rectum after a portion of it has been removed, requires good blood supply and oxygenation to the bowel tissue. The device in this study is intended to non-invasively measure the percent of oxygen in the bowel tissue.

The main purpose of the study is to assess the safety and tolerability of AZD9829 in different dose levels for patients with hematological malignancies.

AZD9829 is considered investigtional, which means it is not approved by the U.S. Food and Drug Administration (FDA). 

This Phase Ib/III study (CAPItello-292) aims to evaluate the efficacy, safety and the degree of added benefit of capivasertib combined with CDK4/6i and fulvestrant in participants with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer.

The purpose of this research study is to better understand the causes of fatty liver recurrence and the development of metabolic illnesses such as diabetes, high blood pressure, weight gain, and abnormal cholesterol levels in patients who have undergone liver transplantation.

This clinical trial is for men and women with Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML).

The purpose of this study is to determine whether the study drug, Rusfertide, is safe and effective for treating Polycythemia Vera for those that require routine phlebotomies (removal of red blood cells) to control their disease.

Participants in this study should have previously participated in a study in which Rusfertide (also known as PTG-300) was being studied. Participants will continue to receive Rusfertide in this study.

The purpose of this study is to see if ABBV-787 (the study drug) is safe and to determine if ABBV-787 has an effect on relapsed or refractory (R/R) Acute Myeloid Leukemia (AML). This study is for patients with Acute Myeloid Leukemia (AML) that have relapsed or are refractory (R/R; meaning they have returned, grown, or progressed during or after one or more prior treatments).

ABBV-787 is considered investigational which means it has not yet been approved by the U.S. Food and Drug Administration (FDA).

The purpose of the study is to collect more information on the safety of BNT116 in combination with cemiplimab and to see how well combining the study drugs work in treating advanced non-small cell lung cancer (NSCLC).
   
The study is researching an investigational drug, called BNT116, in combination with cemiplimab. Investigational means that it has not yet been approved by the U.S. Food and Drug Administration (FDA) alone or in combination with other drugs.